ADORA3 and hepatocellular carcinoma: In parallel, A3 AR agonists have demonstrated therapeutic potential in various immune-mediated and proliferative disorders, such as plaque psoriasis, hepatocellular carcinoma (HCC), and non-alcoholic steatohepatitis (NASH).